Streetbeat News

Stock Prices

ACXP

Acurx Pharmaceuticals Inc's stock is trading lower after the company published efficacy results from a Phase 2 trial. The company had decided to terminate the Phase 2b vancomycin-controlled trial segment early due to high observed clinical cure rate and no emerging safety concerns. The clinical cure rate for ibezapolstat, to treat C. difficile Infection (CDI), was projected to be at least 90%. Other factors, including the cost and the challenging enrollment due to the COVID-19 pandemic, also influenced the decision. The stock is down more than 31%.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:12 pm

CHRW

Morgan Stanley analyst Ravi Shanker has maintained an 'Underweight' rating on C.H. Robinson Worldwide (NASDAQ:CHRW) and lowered the price target from $62 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:09 pm

ATHM

Autohome Inc reported Q3 2023 revenues of $261.2 million, up 3.4% YoY, but slightly below the consensus of $261.7 million. The company's adjusted earnings per ADS of $0.67 beat the consensus of $0.60. The company is expanding its Autohome Energy Space stores and integrating its used car business to tap into new energy vehicles opportunities. The stock has lost 18.4% YTD but is up by 1.25% at $26.56 on the last check Thursday.

Portfolio Pulse from Anusuya Lahiri

November 02, 2023 | 4:08 pm

IDXX

Barclays has maintained an Overweight rating on IDEXX Laboratories and raised its price target from $590 to $592, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:07 pm

WLK

Westlake Corporation's shares are trading higher following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:06 pm

ALPN

Alpine Immune Sciences Inc (NASDAQ:ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis at the American Society of Nephrology Kidney Week. The treatment showed clinically meaningful improvements in proteinuria and a significant reduction in disease-related biomarkers. The drug has been well tolerated with no severe infections reported. Following the news, ALPN shares are up 39.35% at $14.66.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:04 pm

SYM

Symbotic Inc. (NASDAQ:SYM), an AI company specializing in advanced robotics and automation solutions for warehouses and supply chain operations, has seen significant growth since its IPO in June 2022. The company's stock, which debuted at $10.54, reached a peak of $63.54 and is currently trading at approximately $34. An initial investment of $1,000 in Symbotic at its opening day price would now be worth $3,230.

Portfolio Pulse from Chris Bibey

November 02, 2023 | 4:03 pm

CANO

Cano Health, Inc. (NYSE: CANO) has completed a 1-for-100 reverse stock split of its Class A and Class B common stock, following approval by the company's stockholders and its Board of Directors. The reverse stock split is expected to enable the company's Class A common stock to regain compliance with the New York Stock Exchange's listing rules. The company's Class A common stock will begin trading on a split-adjusted basis on November 3, 2023. The total number of Class A and Class B common stock authorized for issuance will be reduced significantly. The company believes the reverse stock split will increase the price per share of the company's Class A common stock and make it more attractive to a broader range of investors.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:03 pm

BX

A significant bearish stance has been taken on Blackstone (NYSE:BX) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 30% bullish and 70% bearish. Whales have been targeting a price range from $65.0 to $130.0 for Blackstone over the last 3 months. The current price of BX is up 2.35% at $96.97. Major financial institutions have maintained their positive ratings on Blackstone, with price targets ranging from $105 to $120.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 4:02 pm

MMI

Marcus & Millichap (NYSE:MMI) is set to release its quarterly earnings report on November 3, 2023. Analysts estimate an earnings per share (EPS) of $-0.26. The company's past performance shows a mixed impact on the share price post-earnings release. The stock is currently trading at $29.22, down 13.9% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 02, 2023 | 4:02 pm